Trial Profile
Efficacy of Ledipasvir/Sofosbuvir plus Ribavirin (SOF/LDV+RBV) in patient with chronic hepatitis C genotype 3 and compensated liver disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2018
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 09 Oct 2018 New trial record